Neurodevelopmental Disorder with Microcephaly and Seizures CRISPR Cell Models

Neurodevelopmental disorder with microcephaly and seizures (NDMS) is a rare, severe condition characterized by reduced head circumference (microcephaly) and early-onset seizures. According to the World Health Organization (WHO), neurodevelopmental disorders affect approximately 1 in 6 children globally, with microcephaly being a key indicator of underlying brain maldevelopment. The National Cancer Institute (NCI) does not track NDMS specifically, as it is not a cancer; however, the condition is associated with significant morbidity, including intellectual disability, motor deficits, and reduced life expectancy. Risk factors include genetic mutations in genes regulating centrosome function and cell division (e.g., ASPM, WDR62, CENPJ). There is no standardized 5-year survival data due to the rarity and heterogeneity of the disorder, but severe cases often lead to early childhood mortality.

NDMS is an ideal model for studying neurogenesis, cortical development, and seizure mechanisms. The disorder encompasses multiple subtypes linked to distinct genetic defects, providing a spectrum of molecular perturbations. Public datasets from NCBI Gene and ClinVar catalog over 100 pathogenic variants in genes such as ASPM, WDR62, CENPJ, and STIL. Open questions include how specific mutations disrupt neural progenitor cell proliferation, how microcephaly predisposes to seizures, and whether targeted gene correction can restore normal brain development. Gene-edited cell models are essential to address these questions.

The pathogenesis of NDMS involves disrupted centrosome function and impaired neurogenesis. Key pathways include:

• • Centrosome duplication and maturation: Mutations in ASPM, WDR62, and CENPJ impair centrosome assembly, leading to mitotic spindle defects and reduced neural progenitor cell proliferation.
• • DNA damage response: Defects in the ATM/ATR pathway (e.g., via MCPH1 mutations) cause genomic instability and premature differentiation.
• • Wnt/beta-catenin signaling: Altered Wnt signaling affects cortical neurogenesis and stem cell maintenance.
• • Seizure generation: Microcephaly-associated cortical malformations create hyperexcitable neuronal circuits, often involving GABAergic interneuron dysfunction.

Data from ClinVar, NCBI Gene, and COSMIC (for somatic mutations in related pathways).

Key signaling networks implicated in NDMS:

• • Centrosome signaling network: ASPM, WDR62, CENPJ, STIL, and CDK5RAP2 form a complex regulating mitotic spindle orientation and neural progenitor division.
• • DNA damage response network: MCPH1, ATM, and ATR coordinate cell cycle checkpoints; loss leads to premature differentiation.
• • Wnt/beta-catenin pathway: Beta-catenin stabilization promotes neural stem cell proliferation; dysregulation causes microcephaly.
• • Notch signaling: Notch1 and Delta-like ligands regulate neural progenitor maintenance; altered signaling reduces cortical surface area.
• • GABAergic signaling: Reduced interneuron migration due to microcephaly leads to excitation/inhibition imbalance and seizures.

Organoid models offer 3D architecture and cell-type diversity, enabling study of cortical development and seizure-like activity.

• • GEMM (Genetically Engineered Mouse Models): Aspm knockout mice show microcephaly and reduced cortical thickness.
• • Induced models: In utero electroporation of shRNA against Wdr62 in mice causes neuronal migration defects.
• • Zebrafish models: wdr62 morphants exhibit microcephaly and seizure-like behavior.
• • Rat models: CENPJ mutant rats display microcephaly and spontaneous seizures.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations found in NDMS patients. For example, ASPM knockout in SH-SY5Y cells recapitulates centrosome defects, while WDR62 knock-in models allow study of missense variants. Commercially available, sequence-verified knockout and knock-in models accelerate research by providing reproducible, isogenic backgrounds. These models are essential for functional validation of novel variants and drug screening. No specific companies are named.

Knockout cell lines for ASPM, WDR62, and CENPJ are used to validate the functional impact of patient mutations. For example, ASPM knockout in neural progenitor cells reduces proliferation and increases apoptosis. Knock-in lines with specific missense mutations (e.g., WDR62 p.R438H) confirm loss of centrosome localization. These models enable high-throughput CRISPR screens to identify genetic modifiers of microcephaly.

Isogenic pairs (wild-type vs. mutant) are used to screen compounds that rescue neurogenesis defects. For instance, screening of a kinase inhibitor library in ASPM knockout neural stem cells identified compounds that restore proliferation. Resistance modeling is less common but can be applied to study how cells adapt to centrosome loss.

CRISPR synthetic lethality screens in ASPM-deficient cells can identify vulnerabilities specific to microcephaly mutations. For example, loss of ASPM sensitizes cells to inhibitors of the DNA damage response, suggesting potential therapeutic targets. Proteomic analysis of knockout cells reveals biomarkers such as altered centrosomal protein levels.